CSCID (Cosciens Biopharma) Cash per Share: $4.72 (As of Mar. 2026)

What is Cosciens Biopharma Cash per Share?

Cosciens Biopharma CSCID -68.03% 61 Cash per Share is $4.72 as of Mar. 2026. GuruFocus rates CSCID with a GF Score™ of 61/100 and a GF Value™ of $6.57 (Fairly Valued). The stock has 6 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Cosciens Biopharma's Cash per Share for the quarter that ended in Mar. 2026 was $4.72.

Cosciens Biopharma (OTCPK:CSCID) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Cosciens Biopharma Cash per Share Related Terms

Cosciens Biopharma Cash per Share Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Cash per Share Chart

Cosciens Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

9.99

16.55

10.84

15.66

6.89

Cosciens Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															13.12	8.82	8.03	6.89	4.72

61GF Score

Cosciens Biopharma Inc CSCID

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cosciens Biopharma Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Cosciens Biopharma's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	7.307	/	1.06
	=	6.89

Cosciens Biopharma's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	5.005	/	1.06
	=	4.72

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $4.72 mean?

Cosciens Biopharma (CSCID) has a Cash per Share of $4.72 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Cosciens Biopharma and its competitors.

Is Cosciens Biopharma's Cash per Share too high?

Cosciens Biopharma's current Cash per Share is $4.72. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Cosciens Biopharma's Cash per Share compare to VRTX and REGN?

Cosciens Biopharma's Cash per Share of $4.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Cosciens Biopharma and its competitors. Cosciens Biopharma's current Cash per Share is $4.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cosciens Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Fairly Valued. The stock's GF Value™ is $6.57, compared to a current price of $7.00 — trading 6.5% above its estimated fair value. The current Cash per Share is $4.72. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current Cash per Share is $4.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCID) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued. The current stock price of $7.00 is trading 6.5% above its estimated GF Value™ of $6.57. GuruFocus considers Cosciens Biopharma to be Fairly Valued.

Key valuation signals for CSCID:

Cash per Share: $4.72
GF Value™: $6.57 vs. price of $7.00 (6.5% above fair value)
GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:GLOW XCNQ:SKNY TSXV:MRVL TSXV:HEM NEOE:BMND XCNQ:PREV XCNQ:DOSE XCNQ:BLAB TSXV:KNE TSX:APS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges ET8:Germany CSCI:Canada

Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3

Website https://www.cosciensbio.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.

61GF Score

Get the complete analysis for CSCID

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00

Price

$6.57

GF Value

View CSCID Analysis

See Cash per Share data for all stocks →